Forcyte Biotechnologies Analysis
What is Forcyte Biotechnologies?
Forcyte Biotechnologies is a biotechnology company that discovers drugs by measuring how cells generate contractile force. It uses patented bioMEMS technology and the contractome to screen human cells at scale. The company says it is charting human mechanobiology to find treatments for diseases such as fibrosis.
Location
1100 Glendon Ave, Los Angeles, California 90024, United States
Employees
1-10
Founded
2017
Revenue
<$5M
Product Features & Capabilities
- FLECS tissuoid contraction assays, FLECS single-cell contractility assays, custom FLECS substrate development, mechanobiology dataset, drug discovery platform for small molecules, mapping genomics and pharmacology to mechanical cell function.
Who are the founders of Forcyte Biotechnologies
IP
Ivan Pushkarsky
CEO and Co-founder
DD
Dino Di Carlo
Co-founder
Investors
- Y Combinator
- Milestone Partners
- Acequia Capital
- Jude Gomila
- Pioneer Fund
- Bali Venture Partners
- Sprint VC
Competitors Overview
Forcyte Biotechnologies operates in the mechanobiology sector, focusing on mapping genomics and pharmacology to mechanical cell function. Its main competitors include:
-
Syd Labs: Founded in 2010, Syd Labs has a reported revenue of $10.5 million and focuses on biotechnological advancements, particularly in drug discovery.
-
Proteos: With a revenue of $6.4 million, Proteos specializes in protein production and analysis, providing tools that may complement Forcyte's mechanobiology focus.
-
G&P Biosciences: This company operates within the biotechnology field, although specific details about its unique advantages compared to Forcyte are not well-documented.
-
ExonBIO: Similar to Forcyte, ExonBIO is involved in biotechnology but lacks detailed information on its competitive edge.
-
Neomorph: A competitor in the biotechnology sector, Neomorph offers alternative solutions in drug development.
-
Neumora Therapeutics: This company is also focused on drug development, potentially overlapping with Forcyte's market.
-
KBP Biosciences: Competes in the biotechnology market, although specific advantages are not highlighted.
Forcyte's unique selling proposition lies in its proprietary FLECS Platform, which emphasizes mechanobiology and the relationship between cell function and therapeutic outcomes, potentially giving it an edge in drug discovery focused on mechanobiology.
Market Focus
Forcyte Biotechnologies primarily focuses on the biotechnology industry, specifically in the field of mechanobiology, which involves mapping genomics and pharmacology to mechanical cell function to develop more effective therapies.
See something that needs updating? Suggest edits to this profile.